163 related articles for article (PubMed ID: 28697993)
1. Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease.
Akoumianakis I; Antoniades C
Vascul Pharmacol; 2017 Sep; 96-98():1-4. PubMed ID: 28697993
[TBL] [Abstract][Full Text] [Related]
2. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
[TBL] [Abstract][Full Text] [Related]
3. The regulatory role of DPP4 in atherosclerotic disease.
Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection.
Tomovic K; Lazarevic J; Kocic G; Deljanin-Ilic M; Anderluh M; Smelcerovic A
Med Res Rev; 2019 Jan; 39(1):404-422. PubMed ID: 29806214
[TBL] [Abstract][Full Text] [Related]
5. Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress.
Piao L; Li Y; Narisawa M; Shen X; Cheng XW
Int Heart J; 2021 May; 62(3):470-478. PubMed ID: 33994495
[TBL] [Abstract][Full Text] [Related]
6. Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword.
Qi XY; Qu SL; Xiong WH; Rom O; Chang L; Jiang ZS
Cardiovasc Diabetol; 2018 Oct; 17(1):134. PubMed ID: 30305178
[TBL] [Abstract][Full Text] [Related]
7. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence.
Fadini GP; Albiero M; Avogaro A
Vascul Pharmacol; 2015 Oct; 73():1-3. PubMed ID: 26254108
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: Modulation of oxidative stress and inflammation.
Xin M; Jin X; Cui X; Jin C; Piao L; Wan Y; Xu S; Zhang S; Yue X; Wang H; Nan Y; Cheng X
Chem Biol Interact; 2019 Dec; 314():108842. PubMed ID: 31586451
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.
Zhang J; Chen Q; Zhong J; Liu C; Zheng B; Gong Q
Front Immunol; 2019; 10():1050. PubMed ID: 31134095
[TBL] [Abstract][Full Text] [Related]
11. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Xie W; Song X; Liu Z
Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
[TBL] [Abstract][Full Text] [Related]
12. Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH
Salaga M; Binienda A; Draczkowski P; Kosson P; Kordek R; Jozwiak K; Fichna J
Peptides; 2018 Oct; 108():34-45. PubMed ID: 30179653
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
14. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration.
Salaga M; Mokrowiecka A; Zielinska M; Malecka-Panas E; Kordek R; Kamysz E; Fichna J
J Pharmacol Exp Ther; 2017 Oct; 363(1):92-103. PubMed ID: 28724693
[TBL] [Abstract][Full Text] [Related]
15. Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV.
Zeng Z; Luo JY; Zuo FL; Yu R; Zhang Y; Ma HQ; Chen SW
Lett Appl Microbiol; 2016 Mar; 62(3):250-5. PubMed ID: 26482681
[TBL] [Abstract][Full Text] [Related]
16. DPP-IV inhibitors: Beyond glycaemic control?
Kwok AJ; Mashar M; Khavandi K; Sabir I
Trends Cardiovasc Med; 2014 May; 24(4):157-64. PubMed ID: 24296298
[TBL] [Abstract][Full Text] [Related]
17. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
De S; Banerjee S; Kumar SKA; Paira P
Mini Rev Med Chem; 2019; 19(2):88-97. PubMed ID: 29692250
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides.
Lacroix IM; Li-Chan EC
Peptides; 2015 Jul; 69():19-25. PubMed ID: 25828735
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
Nishida S; Matsumura T; Senokuchi T; Murakami-Nishida S; Ishii N; Morita Y; Yagi Y; Motoshima H; Kondo T; Araki E
Biochem Biophys Res Commun; 2020 Mar; 524(1):8-15. PubMed ID: 31964532
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease　- Recent Insights Focusing on Angiogenesis and Neovascularization.
Lei Y; Hu L; Yang G; Piao L; Jin M; Cheng X
Circ J; 2017 May; 81(6):770-776. PubMed ID: 28344207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
